Litigation Details for ViiV Healthcare Company v. Gilead Sciences, Inc. (D. Del. 2018)

ViiV Healthcare Company v. Gilead Sciences, Inc. (D. Del. 2018)

Docket		Date Filed	2018-02-06
Court	District Court, D. Delaware	Date Terminated	2022-02-01
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Christopher J. Burke
Parties	VIIV HEALTHCARE COMPANY
Patents	8,129,385; 9,216,996
Attorneys	John M. Hughes
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for ViiV Healthcare Company v. Gilead Sciences, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-12-22	162	Redacted Document	applied to the patent-in-suit (U.S Patent No. 8,129,385, the “’385 patent”) and related applications…medication infringes two claims of ViiV’s U.S. Patent No. 8,129,385 under the doctrine of equivalents. …that the Patent Office did not really consider the patent-in-suit when granting Gilead’s patent for …its own patent over the ’385 patent. These conclusions would apply equally to the patent- in-suit…the ’385 Patent and Gilead’s Patent Does Not Bear on Whether the Two Patents Include	External link to document
2020-02-04	174	Opinion - Memorandum Opinion	infringing United States Patent Number 8,129,385 (the #385 patent). The #385 patent covers pharmaceutical…principle of patent law that the claims of a 2 patent define the…requirements for a patent.") ( citation omitted). It is the claims-not the patent's written description…Bictegravir infringes claims 2 and 6 of the #3 85 patent under the doctrine of equivalents. That doctrine… literally infringe upon the express terms of a patent claim may nonetheless be found to infringe if	External link to document
2020-02-09	176	Notice of Service	Dobkin, M.D. Regarding Infringement of U.S. Patent No. 8,129,385; (3) Reply Expert Report of Jennifer Dressman…Guengerich, Ph.D., Regarding Infringement of U.S. Patent No. 8,129,385; (6) Reply Expert Report of Kenneth M. Merz…Gilead Sciences, Inc.s Infringement of U.S. Patent No. 8,129,385; (7) Supplemental Reply Expert Report of…Gilead Sciences, Inc.s Infringement of U.S. Patent No. 8,129,385; (8) Expert Report of Timothy Simcoe, Ph.D…Gilead Sciences, Inc.s Infringement of U.S. Patent No. 8,129,385 filed by Shionogi & Co., Ltd., ViiV Healthcare	External link to document
2020-04-21	235	Redacted Document	claimed embodiment of claims 2 and 6 of U.S. Patent 8,129,385) and bictegravir (“BIC) sodium (“BIC sodium…claimed embodiment of claims 2 and 6 of U.S. Patent 8,129,385) and bictegravir (“BIC”) are insubstantial…INC.’S INFRINGEMENT OF U.S. PATENT NO. 8,129,385 …Gilead Sciences, Inc.’s Infringement of U.S. Patent No. 8,129,385 (“Merz Opening Report”), the February …Gilead Sciences, Inc.’s Infringement of U.S. Patent No. 8,129,385 (“Merz Reply Report”), and the February	External link to document
2018-02-06	3		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,129,385. (crb) (Entered: …2018 2 February 2022 1:18-cv-00224 830 Patent Plaintiff District Court, D. Delaware	External link to document
2020-07-06	313	Order - -Memorandum and Order	judgment on the basis that claim 6 of U.S. Patent No. 8,129,385 specifically excludes compounds with bicyclic…2018 2 February 2022 1:18-cv-00224 830 Patent Plaintiff District Court, D. Delaware	External link to document